Engineered Hematopoietic Stem Cells for Antigen-Sparing Cancer Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing targeted therapies struggle to selectively target cancer cells without harming normal cells, as they often rely on lineage-specific proteins also present in normal cell populations, leading to detrimental effects.

Innovation Solution

Genetically engineered hematopoietic stem cells with modified or edited lineage-specific cell-surface antigens that retain partial biological activity while escaping targeting by cytotoxic agents, allowing them to direct therapies against cells requiring such antigens for survival.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If targeted therapies use lineage-specific cell-surface antigens to identify and eliminate target cells, then therapeutic effectiveness is improved, but normal cells expressing the same antigens are harmed

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidharm to normal cells

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by creating heterogeneous cell populations where only a subset of cells (cancer cells) express the target antigen while normal cells express a modified version. This is achieved through genetic engineering of hematopoietic stem cells to produce cells with differential antigen expression, allowing targeted therapy to selectively eliminate cancer cells while sparing normal cells that express the modified antigen form

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs parameter changes by modifying the antigen structure through genetic engineering. The modified antigen retains sufficient biological activity to maintain normal cell function but has altered epitopic properties that prevent recognition by cytotoxic agents. This parameter modification allows the same antigen to serve dual purposes: maintaining cellular function while evading therapeutic targeting

Inventive Principle:

Principle #35Parameter changes

2Reliability

If targeted therapies eliminate all cells expressing a specific antigen, then cancer cells are effectively treated, but necessary cell populations are destroyed

Engineering Contradiction:

Improvecancer treatment effectivenessVSAvoidcell population survival

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent creates functional differentiation within the same cell lineage by engineering hematopoietic stem cells to produce daughter cells with modified antigen expression. Normal cells maintain the modified antigen form that preserves cellular function, while cancer cells retain or reacquire the wild-type antigen expression, enabling selective elimination of cancer cells while preserving essential normal cell populations

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent inverts the traditional approach by making the normal cells the ones with modified antigen expression rather than the cancer cells. This inversion allows normal cells to escape targeted therapy while cancer cells become the targets, reversing the typical pattern where normal cells are inadvertently harmed by broad-spectrum antigen targeting

Inventive Principle:

Principle #13The other way round (Inversion)

Data Source

PatentUS12622929B2Genetically engineered hematopoietic stem cells and uses thereof

Publication Date: 2026.05.12 SYZYGYMED INC

AI summary

Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.